**9. Tocilizumab**

In a recent review, that has included 20 publications about 47 BS patients with different organ involvements refractory to previous treatment with conventional immunosuppressives and biologic agents, tocilizumab failed to improve patients with gastrointestinal involvement, with even exacerbation of symptoms in some patients [27].
